Skip to main content

Table 3 Genotype frequencies and ORs associated with each gene polymorphism in breast cancer cases and controls

From: Discovery of breast cancer risk genes and establishment of a prediction model based on estrogen metabolism regulation

Gene and SNPs

Genotype

Control n (%)

Case n (%)

P-value#

OR (95% CI)

P –value*

CYP19A1 (rs700519)

GG

97 (69.3%)

92 (65.7%)

0.813

1

–

GA

37 (26.4%)

41 (29.3%)

1.17 (0.69–1.98)

0.564

AA

6 (4.3%)

7 (5.0%)

1.23 (0.40–3.80)

0.719

CYP1A1 (rs1048943)

TT

100 (71.4%)

80 (57.1%)

0.007

1

–

TC

31 (22.2%)

55 (39.3%)

2.37 (1.27–4.43)

0.003

CC

9 (6.4%)

5 (3.6%)

1.10 (0.30–4.00)

0.528

CYP1A1 (rs4649903)

AA

68 (48.6%)

58 (41.4%)

0.300

1

–

AG

56 (40.0%)

58 (41.4%)

 

1.21 (0.73–2.02)

0.453

GG

16 (11.4%)

24 (17.1%)

 

1.76 (0.85–3.62)

0.126

CYP1B1 (rs1056827)

CC

92 (65.7%)

80 (57.1%)

0.004

1

–

CA

48 (34.3%)

50 35.7%)

1.20 (0.73–1.97)

0.802

AA

0 (0.0%)

10 (7.2%)

6.90 (1.50–31.76)

0.001

CYP1B1 (rs1056836)

GG

90 (64.3%)

116 (82.9%)

0.002

1

–

GC

44 (31.4%)

21 (15.0%)

 

0.37 (0.21–0.67)

0.001

CC

6 (4.3%)

3 (2.1%)

 

0.39 (0.10–1.59)

0.189

HSD17B1 (rs605059)

GG

47 (33.6%)

46 (32.9%)

0.713

1

–

GA

73 (52.1%)

69 (49.3%)

 

0.97 (0.57–1.63)

0.896

AA

20 (14.3%)

25 (17.8%)

 

1.28 (0.63–2.61)

0.502

COMT (rs4680)

GG

91 (65.0%)

80 (57.1%)

0.402

1

–

GA

42 (30.0%)

51 (36.4%)

 

1.38 (0.83–2.29)

0.212

AA

7 (5.0%)

9 (6.4%)

 

1.46 (0.52–4.11)

0.470

SULT1A1 (rs1042028)

CC

117 (83.6%)

98 (70.0%)

0.029

1

–

CT

20 (14.3%)

37 (26.4%)

 

2.21 (1.20–4.05)

0.010

TT

3 (2.1%)

5 (3.6%)

 

1.99 (0.46–8.54)

0.354

UGT2B7 (rs7439366)

CC

69 (49.30%)

64 (45.7%)

0.824

1

–

CT

60 (42.80%)

65 (46.4%)

 

1.17 (0.72–1.90)

0.533

TT

11 (7.90%)

11 (7.90%)

 

1.08 (0.44–2.66)

0.870

ZNF365 (rs10822013)

CC

36 (25.71%)

43 (30.71%)

0.640

1

–

CT

75 (53.57%)

71 (50.71%)

 

0.79 (0.46–1.37)

0.407

TT

29 (20.71%)

26 (18.57%)

 

0.75 (0.38–1.50)

0.415

FGFR2 (rs2981579)

GG

47 (33.57%)

40 (28.57%)

0.418

1

–

GA

70 (50.00%)

69 (49.29%)

 

1.16 (0.68–1.98)

0.592

AA

23 (16.43%)

31 (22.14%)

 

1.58 (0.80–3.14)

0.188

RAD51B (rs3784099)

GG

111 (79.29%)

109 (77.86%)

0.848

1

–

GA

25 (17.86%)

28 (20.00%)

 

1.14 (0.63–2.08)

0.668

AA

4 (2.86%)

3 (2.14%)

 

0.76 (0.17–3.49)

0.728

TOX3 (rs3803662)

GG

15 (10.71%)

18 (12.86%)

0.664

1

–

GA

61 (43.57%)

54 (38.57%)

 

0.83 (0.51–1.38)

0.475

AA

64 (45.71%)

68 (48.57%)

 

1.13 (0.53–2.43)

0.755

MAP3K1 (rs889312)

CC

42 (30.00%)

35 (25.00%)

0.460

1

–

CA

67 (47.86%)

66 (47.14%)

 

1.18 (0.67–2.08)

0.560

AA

31 (22.14%)

39 (27.86%)

 

1.51 (0.79–2.89)

0.215

HCN1 (rs981782)

CC

16 (11.43%)

25 (17.86%)

0.475

1

–

CA

69 (49.29%)

63 (45.00%)

 

0.92 (0.55–1.53)

0.737

AA

55 (39.29%)

52 (37.14%)

 

1.45 (0.68–3.08)

0.336

  1. Values are presented as number (%) or OR (95% CI)
  2. OR Odds radio, CI Confidence interval, SNP Single nuclear polymorphism
  3. #Comparison of polymorphic genotype distributions in patients with breast cancer and healthy case-controls
  4. *Comparison of wild-type genotypes with heterozygous genotypes and homozygous variant genotypes respectively